Eli Lilly expects 2023 revenue to pass USD 30bn mark
The US-based drugmaker has bag of new launches planned for next year, including tirzepatide in the obesity indication.
by marketwire, translated by daniel pedersen
Pharmaceutical firm Eli Lilly presented its full-year 2023 outlook on Tuesday, spotlighting a revenue hope of USD 30.3–30.8bn.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly increases dividends
For subscribers
Eli Lilly to double Mounjaro production
For subscribers
